↓ Skip to main content

Dove Medical Press

Article Metrics

Omalizumab, an anti-immunoglobulin E antibody: state of the art

Overview of attention for article published in Drug Design, Development and Therapy, February 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
96 Mendeley
Title
Omalizumab, an anti-immunoglobulin E antibody: state of the art
Published in
Drug Design, Development and Therapy, February 2014
DOI 10.2147/dddt.s49409
Pubmed ID
Authors

Cristoforo Incorvaia, Marina Mauro, Marina Russello, Chiara Formigoni, Erminia Ridolo, Riario-Sforza

Abstract

A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 2%
Tunisia 1 1%
Spain 1 1%
Unknown 92 96%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 13 14%
Student > Bachelor 13 14%
Other 12 13%
Researcher 12 13%
Student > Master 8 8%
Other 27 28%
Unknown 11 11%
Readers by discipline Count As %
Medicine and Dentistry 55 57%
Biochemistry, Genetics and Molecular Biology 8 8%
Agricultural and Biological Sciences 8 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Immunology and Microbiology 3 3%
Other 6 6%
Unknown 13 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2014.
All research outputs
#6,709,236
of 12,627,283 outputs
Outputs from Drug Design, Development and Therapy
#320
of 1,340 outputs
Outputs of similar age
#71,909
of 186,153 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 20 outputs
Altmetric has tracked 12,627,283 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,340 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,153 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.